Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Pediatric Ocular Myasthenia Gravis
NCT07298928Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of telitacicept in myasthenia gravis (MG), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Ocular Myasthenia Gravis Rating Scale-q at 24 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07298928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298928.